380 related articles for article (PubMed ID: 25997618)
1. The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
Lin X; Stenvang J; Rasmussen MH; Zhu S; Jensen NF; Tarpgaard LS; Yang G; Belling K; Andersen CL; Li J; Bolund L; Brünner N
BMC Genomics; 2015 May; 16(1):404. PubMed ID: 25997618
[TBL] [Abstract][Full Text] [Related]
2. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
4. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.
Zhou Y; Bollu LR; Tozzi F; Ye X; Bhattacharya R; Gao G; Dupre E; Xia L; Lu J; Fan F; Bellister S; Ellis LM; Weihua Z
Mol Cancer Ther; 2013 Dec; 12(12):2782-91. PubMed ID: 24132143
[TBL] [Abstract][Full Text] [Related]
5. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.
Jensen NF; Stenvang J; Beck MK; Hanáková B; Belling KC; Do KN; Viuff B; Nygård SB; Gupta R; Rasmussen MH; Tarpgaard LS; Hansen TP; Budinská E; Pfeiffer P; Bosman F; Tejpar S; Roth A; Delorenzi M; Andersen CL; Rømer MU; Brünner N; Moreira JM
Mol Oncol; 2015 Jun; 9(6):1169-85. PubMed ID: 25759163
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin: a new agent for colorectal cancer.
Pelley RJ
Curr Oncol Rep; 2001 Mar; 3(2):147-55. PubMed ID: 11177747
[TBL] [Abstract][Full Text] [Related]
8. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
[TBL] [Abstract][Full Text] [Related]
9. Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines.
Moon HH; Kim SH; Ku JL
Oncol Rep; 2016 Jan; 35(1):298-306. PubMed ID: 26497773
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.
Davidson D; Coulombe Y; Martinez-Marignac VL; Amrein L; Grenier J; Hodkinson K; Masson JY; Aloyz R; Panasci L
Invest New Drugs; 2012 Jun; 30(3):1248-56. PubMed ID: 21221710
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
13. Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.
Jansman FG; Idzinga FS; Smit WM; de Graaf JC; Coenen JL; Sleijfer DT; Brouwers JR
Clin Ther; 2005 Mar; 27(3):327-35. PubMed ID: 15878386
[TBL] [Abstract][Full Text] [Related]
14. Gap junction composed of connexin43 modulates 5‑fluorouracil, oxaliplatin and irinotecan resistance on colorectal cancers.
Zou ZW; Chen HJ; Yu JL; Huang ZH; Fang S; Lin XH
Mol Med Rep; 2016 Nov; 14(5):4893-4900. PubMed ID: 27748862
[TBL] [Abstract][Full Text] [Related]
15. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
Kotani D; Yoshino T; Kotaka M; Kawazoe A; Masuishi T; Taniguchi H; Yamazaki K; Yamanaka T; Oki E; Muro K; Komatsu Y; Bando H; Satake H; Kato T; Tsuji A
Invest New Drugs; 2021 Dec; 39(6):1649-1655. PubMed ID: 34019214
[TBL] [Abstract][Full Text] [Related]
17. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Kuebler JP; de Gramont A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Plasencia C; Abad A; Martinez-Balibrea E; Taron M
Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
[TBL] [Abstract][Full Text] [Related]
19. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Aparicio T; Desramé J; Lecomte T; Mitry E; Belloc J; Etienney I; Montembault S; Vayre L; Locher C; Ezenfis J; Artru P; Mabro M; Dominguez S;
Br J Cancer; 2003 Oct; 89(8):1439-44. PubMed ID: 14562014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
